US Stock MarketDetailed Quotes
PRLD Prelude Therapeutics
- 1.300
- +0.412+46.40%
Close Dec 20 16:00 ET
- 1.280
- -0.020-1.54%
Post 20:01 ET
71.55MMarket Cap-0.73P/E (TTM)
1.450High0.937Low4.44MVolume0.937Open0.888Pre Close5.50MTurnover31.48%Turnover RatioLossP/E (Static)55.04MShares6.80052wk High0.46P/B18.34MFloat Cap0.79752wk Low--Dividend TTM14.11MShs Float95.375Historical High--Div YieldTTM57.73%Amplitude0.797Historical Low1.238Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Prelude Therapeutics Stock Forum
Prelude Therapeutics Inc: Plans to Seek a Partner for Future Development of PRT2527 in Hematologic Malignancies
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Wednesday, 11th December at 7:30 am
• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy
• Prelude plans to seek a partner for future development of PRT2527 in hematol...
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics (NASDAQ: PRLD) announced promising initial clinical data for PRT3789, its first-in-class SMARCA2 degrader, in a Phase 1 trial. The drug showed encouraging anti-tumor activityin patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer. Key findings include:
- 3 confirmed partial re...
On July 10, 2024, Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced a clinical collaboration with Merck. This collaboration aims to evaluate the efficacy of Prelude's investigational drug, PRT3789, in combination with Merck's established anti-PD-1 t...
Prelude Therapeutics Announces Clinical Collaboration With Merck to Evaluate PRT3789 in Combination With Keytruda® (Pembrolizumab) in Patients With Smarca4-Mutated Cancers
Prelude Therapeutics has announced a clinical collaboration with Merck to evaluate the combination of Prelude's PRT3789, a selective SMARCA2 degrader, with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with SMARCA4-mutated cancers. The Phase 2 clinical study aims to explore the potential ...
What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the week of June 17-21.
Top 5 Buy Calls:
1. Skyworks upgraded to Buy at B. Riley
$Skyworks Solutions (SWKS.US)$
B. Riley upgraded Skyworks (SWKS) to Buy from Neutral with a price target of $130, up from $96, ahead of the July 8 through 11 SEM...
No comment yet